LINDSEY BRADLEY: Open Payments
NPI 1548002918 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$606 in 27 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $198 · 2025 $606
Food & beverage: $606
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $159 |
| Dexcom, Inc. | 5 | $111 |
| Lilly USA, LLC | 6 | $104 |
| AstraZeneca Pharmaceuticals LP | 5 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $44 |
| ABIOMED | 1 | $26 |
| Corcept Therapeutics | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| Exact Sciences Corporation | 1 | $20 |
| Amgen Inc. | 1 | $14 |
Products named: Ozempic, Dexcom G6 Transmitter, MOUNJARO, FARXIGA, JARDIANCE, AIRSUPRA, Korlym, SHINGRIX.
Industry payments across LA — which companies pay providers there.
